Matches in SemOpenAlex for { <https://semopenalex.org/work/W44375275> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W44375275 endingPage "97" @default.
- W44375275 startingPage "96" @default.
- W44375275 abstract "The present authors report a 2-year study of estrogen therapy for the prevention or reduction of postmenopausal bone loss. The aim of the investigation was to determine the minimum effective dose of estrogen for postmenopausal and oophorectomized women. Of the 150 patients enrolled in the study, 108 completed 2 years of therapy. Thirty patients were allocated to each of four dose levels of conjugated equine estrogens: 1.25, 0.625, 0.3, and 0.15 mg per day. All patients were allocated randomly to a dose level and were compared with 30 patients randomly given nonmatching placebo tablets (Table 1). The mean heights and weights of the groups were comparable and did not change significantly throughout the study. Total serum calcium (corrected for changes in serum albumin) and phosphate were significantly reduced by 0.625 and by 1.25 mg of conjugated estrogens per day but not by any of the lower doses. In the measurements taken before treatment, serum calcium was significantly higher in the group given 0.625 mg per day than in all other groups. Serum phosphate also was higher in the 0.625-mg and 1.25-mg groups before therapy. The reasons for these differences are obscure, but the finding does not interfere with the interpretation of the results. In conjunction with the changes in serum levels, urinary calcium was reduced only in those groups given 0.625 and 1.25 mg of estrogen per day. In the pretreatment measurements, urinary calcium was somewhat reduced in the group given 0.625 mg per day, as compared with other groups. This is perhaps compatible with the slightly higher level of serum calcium. Despite this lower starting point, 0.625 mg of conjugated equine estrogens per day reduces urinary calcium significantly. Urinary hydroxyproline also was significantly reduced at 0.625 and 1.25 mg per day but not at the lower dose levels. Bone mineral content, estimated by single photon absorptiometry, fell significantly in the placebo (0.15− and 0.3− mg-treated) groups, with no significant difference in behavior between groups. Conjugated equine estrogens at 0.625 and 1.25 mg per day afforded significant protection against bone loss. Construction of a dose-response curve suggested that a 50 per cent response rate would be obtained at 0.45 mg of estrogens per day." @default.
- W44375275 created "2016-06-24" @default.
- W44375275 creator A5019734320 @default.
- W44375275 creator A5063621780 @default.
- W44375275 creator A5072325890 @default.
- W44375275 date "1985-02-01" @default.
- W44375275 modified "2023-10-14" @default.
- W44375275 title "The Minimum Effective Dose of Estrogen for Prevention of Postmenopausal Bone Loss" @default.
- W44375275 doi "https://doi.org/10.1097/00006254-198502000-00016" @default.
- W44375275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6374537" @default.
- W44375275 hasPublicationYear "1985" @default.
- W44375275 type Work @default.
- W44375275 sameAs 44375275 @default.
- W44375275 citedByCount "171" @default.
- W44375275 countsByYear W443752752012 @default.
- W44375275 countsByYear W443752752014 @default.
- W44375275 countsByYear W443752752015 @default.
- W44375275 countsByYear W443752752016 @default.
- W44375275 countsByYear W443752752017 @default.
- W44375275 countsByYear W443752752019 @default.
- W44375275 crossrefType "journal-article" @default.
- W44375275 hasAuthorship W44375275A5019734320 @default.
- W44375275 hasAuthorship W44375275A5063621780 @default.
- W44375275 hasAuthorship W44375275A5072325890 @default.
- W44375275 hasConcept C126322002 @default.
- W44375275 hasConcept C126894567 @default.
- W44375275 hasConcept C134018914 @default.
- W44375275 hasConcept C142724271 @default.
- W44375275 hasConcept C170033053 @default.
- W44375275 hasConcept C204787440 @default.
- W44375275 hasConcept C27081682 @default.
- W44375275 hasConcept C2776697488 @default.
- W44375275 hasConcept C2777164284 @default.
- W44375275 hasConcept C3018603563 @default.
- W44375275 hasConcept C3020687571 @default.
- W44375275 hasConcept C519063684 @default.
- W44375275 hasConcept C71924100 @default.
- W44375275 hasConcept C77411442 @default.
- W44375275 hasConceptScore W44375275C126322002 @default.
- W44375275 hasConceptScore W44375275C126894567 @default.
- W44375275 hasConceptScore W44375275C134018914 @default.
- W44375275 hasConceptScore W44375275C142724271 @default.
- W44375275 hasConceptScore W44375275C170033053 @default.
- W44375275 hasConceptScore W44375275C204787440 @default.
- W44375275 hasConceptScore W44375275C27081682 @default.
- W44375275 hasConceptScore W44375275C2776697488 @default.
- W44375275 hasConceptScore W44375275C2777164284 @default.
- W44375275 hasConceptScore W44375275C3018603563 @default.
- W44375275 hasConceptScore W44375275C3020687571 @default.
- W44375275 hasConceptScore W44375275C519063684 @default.
- W44375275 hasConceptScore W44375275C71924100 @default.
- W44375275 hasConceptScore W44375275C77411442 @default.
- W44375275 hasIssue "2" @default.
- W44375275 hasLocation W443752751 @default.
- W44375275 hasLocation W443752752 @default.
- W44375275 hasOpenAccess W44375275 @default.
- W44375275 hasPrimaryLocation W443752751 @default.
- W44375275 hasRelatedWork W1974087872 @default.
- W44375275 hasRelatedWork W1975979596 @default.
- W44375275 hasRelatedWork W1977053835 @default.
- W44375275 hasRelatedWork W1986049049 @default.
- W44375275 hasRelatedWork W1998644272 @default.
- W44375275 hasRelatedWork W2037193503 @default.
- W44375275 hasRelatedWork W2076325181 @default.
- W44375275 hasRelatedWork W2320244679 @default.
- W44375275 hasRelatedWork W2886708363 @default.
- W44375275 hasRelatedWork W2279599896 @default.
- W44375275 hasVolume "40" @default.
- W44375275 isParatext "false" @default.
- W44375275 isRetracted "false" @default.
- W44375275 magId "44375275" @default.
- W44375275 workType "article" @default.